Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells

Cancer Biology and Therapy

Volumn 13, Issue 11, 2012, Pages 1082-1090

  Tang, Baiqing ^a   Testa, Joseph R ^a   Kruger, Warren D ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Mesothelioma; Methionine; Osteosarcoma; Purine

Indexed keywords

5' METHYLTHIOADENOSINE; 5' METHYLTHIOADENOSINE PHOSPHORYLASE; ADENINE; ADENOSINE PHOSPHATE; ALANOSINE; ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLUOROURACIL; THYMIDINE; TIOGUANINE;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CANCER INHIBITION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME MECHANISM; FIBROBLAST; FIBROSARCOMA; GENE DELETION; GENE LOCUS; HUMAN; HUMAN CELL; MESOTHELIOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL;

ADENOSINE; ANIMALS; CELL LINE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FIBROSARCOMA; FLUOROURACIL; HUMANS; MESOTHELIOMA; MICE; MICE, INBRED C57BL; NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE; THIOGUANINE; THIONUCLEOSIDES;

EID: 84865857782     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21115     Document Type: Article

References (34)

1. Robins RK, Revankar GR. Purine analogs and related nucleosides and nucleotides as antitumor agents. Med Res Rev 1985; 5:273-96; PMID:3894832; http://dx.doi.org/10.1002/med.2610050302.
2. Elgemeie GH. Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites. Curr Pharm Des 2003; 9:2627-42; PMID:14529546; http://dx.doi.org/10.2174/1381612033453677.
3. Nobori T, Takabayashi K, Tran P, Orvis L, Batova A, Yu AL, et al. Genomic cloning of methylthioadenosinephosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci USA 1996; 93:6203-8; PMID:8650244; http://dx.doi.org/10.1073/pnas.93.12.6203.
4. Subhi AL, Tang B, Balsara BR, Altomare DA, Testa JR, Cooper HS, et al. Loss of methylthioadenosinephosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin Cancer Res 2004; 10:7290-6; PMID:15534104; http://dx.doi.org/10.1158/1078-0432.CCR-04-0972.
5. Hustinx SR, Hruban RH, Leoni LM, Iacobuzio-Donahue C, Cameron JL, Yeo CJ, et al. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer BiolTher 2005; 4:83-6; PMID:15662124; http://dx.doi.org/10.4161/cbt.4.1.1380.
6. Schmid M, Malicki D, Nobori T, Rosenbach MD, Campbell K, Carson DA, et al. Homozygous deletions of methylthioadenosinephosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene 1998; 17:2669-75; PMID:9840931; http://dx.doi.org/10.1038/sj.onc.1202205.
7. Brat DJ, James CD, Jedlicka AE, Connolly DC, Chang E, Castellani RJ, et al. Molecular genetic alterations in radiation-induced astrocytomas. Am J Pathol 1999; 154:1431-8; PMID:10329596; http://dx.doi.org/10.1016/S0002-9440(10)65397- 7.
8. Suzuki T, Maruno M, Wada K, Kagawa N, Fujimoto Y, Hashimoto N, et al. Genetic analysis of human glioblastomas using a genomic microarray system. Brain Tumor Pathol 2004; 21:27-34; PMID:15696966; http://dx.doi.org/10.1007/ BF02482174.
9. Stadler WM, Olopade OI. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res 1996; 24:239-44; PMID:8873383; http://dx.doi.org/10.1007/BF00295899.
10. García-Castellano JM, Villanueva A, Healey JH, Sowers R, Cordon-Cardo C, Huvos A, et al. Methylthioadenosinephosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 2002; 8:782-7; PMID:11895909.
11. Dreyling MH, Roulston D, Bohlander SK, Vardiman J, Olopade OI. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer 1998; 22:72-8; PMID:9591637; http://dx.doi.org/10.1002/ (SICI)1098-2264(199805)22:1〈72::AID-GCC10〉3.0.CO;2-K.
12. M'soka TJ, Nishioka J, Taga A, Kato K, Kawasaki H, Yamada Y, et al. Detection of methylthioadenosinephosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay. Leukemia 2000; 14:935-40; PMID:10803528; http://dx.doi.org/10.1038/sj.leu.2401771.
13. Mirebeau D, Acquaviva C, Suciu S, Bertin R, Dastugue N, Robert A, et al.; EORTC-CLG. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica 2006; 91:881-5; PMID:16818274.
14. Batova A, Diccianni MB, Nobori T, Vu T, Yu J, Bridgeman L, et al. Frequent deletion in the methylthioadenosinephosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood 1996; 88:3083-90; PMID:8874207.
15. Hori Y, Hori H, Yamada Y, Carrera CJ, Tomonaga M, Kamihira S, et al. The methylthioadenosinephosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia. Int J Cancer 1998; 75:51-6; PMID:9426690; http://dx.doi.org/10.1002/(SICI)1097-0215(19980105)75:1〈51:: AID-IJC9〉3.0.CO;2-0.
16. Karikari CA, Mullendore M, Eshleman JR, Argani P, Leoni LM, Chattopadhyay S, et al. Homozygous deletions of methylthioadenosinephosphorylase in human biliary tract cancers. Mol Cancer Ther 2005; 4:1860-6; PMID:16373701; http://dx.doi.org/10.1158/1535-7163.MCT-05-0103.
17. Chen YJ, Lin SC, Kao T, Chang CS, Hong PS, Shieh TM, et al. Genome-wide profiling of oral squamous cell carcinoma. J Pathol 2004; 204:326-32; PMID:15372456; http://dx.doi.org/10.1002/path.1640.
18. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosinephosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003; 9:2108-13; PMID:12796375.
19. Wong YF, Chung TK, Cheung TH, Nobori T, Chang AM. MTAP gene deletion in endometrial cancer. Gynecol Obstet Invest 1998; 45:272-6; PMID:9623796; http://dx.doi.org/10.1159/000009983.
20. Berasain C, Hevia H, Fernández-Irigoyen J, Larrea E, Caballería J, Mato JM, et al. Methylthioadenosinephosphorylase gene expression is impaired in human liver cirrhosis and hepatocarcinoma. Biochim Biophys Acta 2004; 1690:276-84; PMID:15511635.
21. Christopher SA, Diegelman P, Porter CW, Kruger WD. Methylthioadenosinephosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 2002; 62:6639-44; PMID:12438261.
22. Kadariya Y, Yin B, Tang B, Shinton SA, Quinlivan EP, Hua X, et al. Mice heterozygous for germ-line mutations in methylthioadenosinephosphorylase (MTAP) die prematurely of T-cell lymphoma. Cancer Res 2009; 69:5961-9; PMID:19567676; http://dx.doi.org/10.1158/0008-5472.CAN-09-0145.
23. Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosinephosphorylase: a novel strategy. PLoS One 2009; 4:5735; PMID:19478948; http://dx.doi.org/10.1371/journal.pone.0005735.
24. Ardalan B, Villacorte D, Heck D, Corbett T. Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas. Biochem Pharmacol 1982; 31:1989-92; PMID:6180752; http://dx.doi.org/10.1016/0006-2952(82)90410-5.
25. Tang B, Li YN, Kruger WD. Defects in methylthioadenosinephosphorylase are associated with but not responsible for methionine-dependent tumor cell growth. Cancer Res 2000; 60:5543-7; PMID:11034100.
26. Singh V, Shi W, Evans GB, Tyler PC, Furneaux RH, Almo SC, et al. Picomolar transition state analogue inhibitors of human 5′- methylthioadenosinephosphorylase and X-ray structure with MT-immucillin-A. Biochemistry 2004; 43:9-18; PMID:14705926; http://dx.doi.org/10.1021/bi0358420.
27. Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 2005; 65:8090-5; PMID:16166281; http://dx.doi.org/10.1158/0008-5472. CAN-05-2312.
28. Kindler HL, Burris HA, 3rd, Sandler AB, Oliff IA. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs 2009; 27:75-81; PMID:18618081; http://dx.doi.org/10.1007/s10637-008-9160-1.
29. Simile MM, Banni S, Angioni E, Carta G, De Miglio MR, Muroni MR, et al. 5′-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J Hepatol 2001; 34:386-94; PMID:11322199; http://dx.doi.org/10.1016/S0168-8278(00) 00078-7.
30. Wolford RW, Riscoe MK, Johnson L, Ferro AJ, Fitchen JH. Effect of 5′-methylthioadenosine (a naturally occurring nucleoside) on murine hematopoiesis. Exp Hematol 1984; 12:867-71; PMID:6510486.
31. Moratti EM. Inventor. Pharmaceutical compositions containing 5′-deoxy-5′-methylthioadenosine S-adenosylmethionine and their salts for reducing seborrhea USA 1990. US Patent No. 5753213.
32. Bertino JR, Waud WR, Parker WB, Lubin M. Targeting tumors that lack methylthioadenosinephosphorylase (MTAP) activity: current strategies. Cancer Biol Ther 2011; 11:627-32; PMID:21301207; http://dx.doi.org/10.4161/cbt.11.7. 14948.
33. Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, et al. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosinephosphorylase, an exploitable tumor target. Mol Cancer Ther 2012; 11:775-83; PMID:22252602; http://dx.doi.org/10.1158/1535-7163.MCT-11- 0826.
34. Peters GJ, Schornagel JH, Milano GA. Clinical pharmacokinetics of anti-metabolites. Cancer Surv 1993; 17:123-56; PMID:8137339.